Aquaporin-3 and Aquaporin-5 Facilitate Migration and Cell-Cell Adhesion in Pancreatic Cancer by Modulating Cell Biomechanical Properties.
aquaglyceroporins
aquaporins
atomic force microscopy
cell–cell adhesion
hydrogen peroxide
membrane fluidity
pancreatic cancer
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
12 04 2022
12 04 2022
Historique:
received:
11
02
2022
revised:
05
04
2022
accepted:
08
04
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
27
4
2022
Statut:
epublish
Résumé
Aquaporins are membrane channels responsible for the bidirectional transfer of water and small non-charged solutes across cell membranes. AQP3 and AQP5 are overexpressed in pancreatic ductal adenocarcinoma, playing key roles in cell migration, proliferation, and invasion. Here, we evaluated AQP3 and AQP5 involvement in cell biomechanical properties, cell-cell adhesion, and cell migration, following a loss-of-function strategy on BxPC-3 cells. Silencing of AQP3 and AQP5 was functionally validated by reduced membrane permeability and had implications on cell migration, slowing wound recovery. Moreover, silenced AQP5 and AQP3/5 cells showed higher membrane fluidity. Biomechanical and morphological changes were assessed by atomic force microscopy (AFM), revealing AQP5 and AQP3/5 silenced cells with a lower stiffness than their control. Through cell-cell adhesion measurements, the work (energy) necessary to detach two cells was found to be lower for AQP-silenced cells than control, showing that these AQPs have implications on cell-cell adhesion. These findings highlight AQP3 and AQP5 involvement in the biophysical properties of cell membranes, whole cell biomechanical properties, and cell-cell adhesion, thus having potential implication in the settings of tumor development.
Sections du résumé
BACKGROUND
Aquaporins are membrane channels responsible for the bidirectional transfer of water and small non-charged solutes across cell membranes. AQP3 and AQP5 are overexpressed in pancreatic ductal adenocarcinoma, playing key roles in cell migration, proliferation, and invasion. Here, we evaluated AQP3 and AQP5 involvement in cell biomechanical properties, cell-cell adhesion, and cell migration, following a loss-of-function strategy on BxPC-3 cells.
RESULTS
Silencing of AQP3 and AQP5 was functionally validated by reduced membrane permeability and had implications on cell migration, slowing wound recovery. Moreover, silenced AQP5 and AQP3/5 cells showed higher membrane fluidity. Biomechanical and morphological changes were assessed by atomic force microscopy (AFM), revealing AQP5 and AQP3/5 silenced cells with a lower stiffness than their control. Through cell-cell adhesion measurements, the work (energy) necessary to detach two cells was found to be lower for AQP-silenced cells than control, showing that these AQPs have implications on cell-cell adhesion.
CONCLUSION
These findings highlight AQP3 and AQP5 involvement in the biophysical properties of cell membranes, whole cell biomechanical properties, and cell-cell adhesion, thus having potential implication in the settings of tumor development.
Identifiants
pubmed: 35455986
pii: cells11081308
doi: 10.3390/cells11081308
pmc: PMC9030499
pii:
doi:
Substances chimiques
AQP3 protein, human
0
AQP5 protein, human
0
Aquaporin 5
0
Aquaporin 3
158801-98-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
J Cell Physiol. 2014 Nov;229(11):1787-801
pubmed: 24676973
Int J Pharm. 2021 Apr 15;599:120463
pubmed: 33711474
Int J Mol Sci. 2018 Jan 03;19(1):
pubmed: 29301341
Molecules. 2021 Apr 29;26(9):
pubmed: 33947079
Int J Mol Sci. 2019 Oct 11;20(20):
pubmed: 31614661
Pflugers Arch. 2004 Jun;448(3):313-8
pubmed: 15107996
Antioxid Redox Signal. 2013 Nov 1;19(13):1447-51
pubmed: 23541115
Biochim Biophys Acta. 2014 May;1840(5):1596-604
pubmed: 24060746
Nanoscale. 2019 Feb 7;11(6):2757-2766
pubmed: 30672545
Genome Biol. 2006;7(2):206
pubmed: 16522221
Front Chem. 2016 Feb 01;4:3
pubmed: 26870725
Cell Mol Life Sci. 2021 Mar;78(6):3073-3085
pubmed: 33231721
Nanomedicine. 2018 Apr;14(3):909-918
pubmed: 29410160
Biochim Biophys Acta. 2015 Oct;1848(10 Pt B):2576-83
pubmed: 25204262
Cell Cycle. 2016 Jun 2;15(11):1415-24
pubmed: 27096894
Cancer Res. 1997 Mar 1;57(5):956-62
pubmed: 9041201
Acta Biomater. 2007 Jul;3(4):413-38
pubmed: 17540628
Biochim Biophys Acta Biomembr. 2021 Sep 1;1863(9):183650
pubmed: 34019902
Int J Mol Sci. 2019 Mar 19;20(6):
pubmed: 30893772
Oncotarget. 2017 Jun 13;8(24):38444-38455
pubmed: 28404978
Beilstein J Nanotechnol. 2021 Dec 14;12:1372-1379
pubmed: 34987950
Nature. 2005 Apr 7;434(7034):786-92
pubmed: 15815633
Int J Mol Sci. 2020 Apr 02;21(7):
pubmed: 32252345
Am J Physiol. 1996 May;270(5 Pt 2):R1078-84
pubmed: 8928909
J Surg Oncol. 2017 Jun;115(8):980-996
pubmed: 28471475
PLoS One. 2013 Dec 20;8(12):e83442
pubmed: 24376702
Oncogenesis. 2016 Jan 25;5:e189
pubmed: 26807644
Clin Invest Med. 2004 Dec;27(6):324-44
pubmed: 15675113
Cell Mol Life Sci. 2016 Apr;73(8):1623-40
pubmed: 26837927
Cancer Lett. 2007 May 18;250(1):36-46
pubmed: 17084522
IUBMB Life. 2017 May;69(5):355-362
pubmed: 28337841
J Phys Chem B. 2007 Mar 29;111(12):3139-50
pubmed: 17388448
ACS Nano. 2010 Aug 24;4(8):4609-20
pubmed: 20731444
Biochim Biophys Acta. 2013 Sep;1828(9):2099-110
pubmed: 23702462
Int J Clin Exp Pathol. 2018 Jan 01;11(1):58-67
pubmed: 31938087
Hypertension. 2003 Dec;42(6):1075-81
pubmed: 14581295
Nanotechnology. 2008 Sep 24;19(38):384003
pubmed: 21832563
Cells. 2019 Sep 14;8(9):
pubmed: 31540078
PLoS One. 2012;7(5):e37435
pubmed: 22624030
Cancer Invest. 1986;4(1):15-23
pubmed: 3754176
Nat Rev Drug Discov. 2014 Apr;13(4):259-77
pubmed: 24625825
Int J Mol Sci. 2021 Feb 12;22(4):
pubmed: 33673336
Nanoscale. 2017 Oct 12;9(39):14897-14906
pubmed: 28949356
Contemp Oncol (Pozn). 2017;21(1):30-34
pubmed: 28435395
Mol Membr Biol. 2006 Jan-Feb;23(1):41-8
pubmed: 16611579
Nat Nanotechnol. 2016 Aug;11(8):687-92
pubmed: 27183056
Biomolecules. 2020 May 22;10(5):
pubmed: 32455962
Annu Rev Med. 2012;63:303-16
pubmed: 22248325
Nat Nanotechnol. 2007 Dec;2(12):780-3
pubmed: 18654431
Cancers (Basel). 2019 Jul 03;11(7):
pubmed: 31277235
Clin Cancer Res. 2010 Jun 1;16(11):2927-31
pubmed: 20484021
PLoS One. 2016 Aug 09;11(8):e0160976
pubmed: 27504956
Mol Aspects Med. 2006 Apr-Jun;27(2-3):126-39
pubmed: 16469371
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Oncogene. 2009 Dec 10;28(49):4326-43
pubmed: 19826415
Oxid Med Cell Longev. 2017;2017:8416763
pubmed: 28819546
J Exp Clin Cancer Res. 2014 May 03;33:38
pubmed: 24887009
IUBMB Life. 2012 Jun;64(6):465-72
pubmed: 22550017
Biophys J. 2015 Oct 6;109(7):1330-3
pubmed: 26445433
PLoS One. 2012;7(6):e38717
pubmed: 22715407
Ther Adv Med Oncol. 2019 Sep 25;11:1758835919875568
pubmed: 31598142